Sir Mark Caulfield

Sir Mark Caulfield graduated in Medicine in 1984 from the London Hospital Medical College, and trained in Clinical Pharmacology at St Bartholomew's Hospital, where he developed a research programme in the molecular genetics of hypertension and translational clinical research.

At Queen Mary University of London, he has made contributions to the discovery of genes related to blood pressure, cardiovascular health, cancer and rare diseases. His research has changed national and international guidance for high blood pressure.

He has won the Lilly Prize of the British Pharmacological Society, the Bjorn Folkow Award of the European Society of Hypertension in 2016, and the Franz Volhard Award of the International Society of Hypertension in 2018.

He was appointed Chief Scientist for Genomics England in 2013, charged with delivery of the 100,000 Genomes Project on whole genome sequencing in rare disease, cancer and infection. He was instrumental in delivering the 100,000 Genomes Project, which has delivered life-changing results for many patients. He worked with NHS England to co-create the National Genomic Test Directory, which offers equitable access to appropriate genomic tests for 56 million people.

He was awarded a knighthood in 2019 for his leadership of the 100,000 Genomes Project. He is a member of the Barts Health NHS Trust Board and the Barking, Havering and Redbridge University Hospitals NHS Trust Board, a member of the MedCity Board, and President of the British Pharmacological Society.